Add Alkem Laboratories, target price Rs 5,700: HDFC Securities
HDFC Securities suggests adding Alkem Laboratories shares, targeting Rs 5,700. Alkem, a large pharmaceutical company, reported its financials. Total income for the quarter was Rs 3467.27 crore. Net profit after tax stood at Rs 640.79 crore. Sales ...

Alkem's key products/revenue segments include Pharmaceuticals, Other Operating Revenue, Export Incentives and Scrap for the year ending 31-Mar-2024.
Financials
For the quarter ended 31-12-2024, the company has reported a Consolidated Total Income of Rs 3467.27 crore, down -2.31% from last quarter Total Income of Rs 3549.15 crore and up 1.46% from last year same quarter Total Income of Rs 3417.51 crore. The company has reported net profit after tax of Rs 640.79 crore in the latest quarter.
The company's top management includes Mr.Basudeo N Singh, Ms.Sudha Ravi, Ms.Sangeeta Singh, Mr.Arun Kumar Purwar, Mr.Sujjain Talwar, Mr.Sarvesh Singh, Mr.Mritunjay Kumar Singh, Mr.Srinivas Singh, Mrs.Madhurima Singh, Mr.Sandeep Singh, Mr.Narendra Kumar Aneja. Company has BSR & Co. LLP as its auditors. As on 31-12-2024, the company has a total of 12 crore shares outstanding.
Investment Rationale
Sales growth to be moderate due to ~8% growth in India formulation business and ~8% growth in international business (ex-US) to partly offset by muted US business (-1% QoQ). Gross margin to see YoY improvement but higher costs towards growth initiatives to keep EBITDA under pressure.
Promoters held 55.66 per cent stake in the company as of 31-Dec-2024, while FIIs owned 10.14 per cent, DIIs $Parser.toNumber($MarketsData-marketResults.newShareHolding.summary.dii.percentage) per cent.
Download ET Markets APP